An observational study in Sexually Transmitted Infections (Not HIV or Hepatitis), Premature Birth and Pregnancy; Infection, sponsored by University of Bern. Completed at 1 site in South Africa. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-16.
Sponsored by University of Bern · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 305 studies in HIV Infections with a site in South Africa — 15 open to participants now, 36 under way, 15 of them phase 3. HIV Infections · South Africa.
Among the 305 studies in HIV Infections with a site in South Africa, this one is the 15th largest by enrollment of the 35 observational ones that give a count, is one of 17 that started in 2021, is one of 35 observational ones, and was the 289th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →15 of the 305 studies in HIV Infections with a site in South Africa are open now. Recruiting first, the newest first:
ViiV Healthcare · Sites in South Africa, Romania, Uganda
ViiV Healthcare · Sites in South Africa
Ages up to 10 days · Healthy volunteers
Emory University · Sites in South Africa
Ages 18+ · Men only · Healthy volunteers
University of Illinois at Chicago · Sites in South Africa
Ages 18+ · Healthy volunteers
University of California, San Francisco · Sites in South Africa
A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
305 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 60 · Phase 2 92 · Phase 3 85 · Phase 4 21
First in 1999; this study’s year is marked. 17 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 603 is above the median of 200 across 781 observational studies indexed under HIV Infections.
Median enrollment 280 across the 267 interventional studies, 513 across the 35 observational. Of the 248 that completed or were terminated, 128 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
77 of 305 have an industry lead sponsor. The 10 most frequent:
University of Bern is the lead sponsor of 209 studies on the registry; 46 are open to participants now.
University of Bern has 2 studies filed under HIV Infections — fewer than ten, so there is no comparison to draw.
9 of the studies in HIV Infections with a site in South Africa that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06694753International AIDS Vaccine InitiativeSafety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall Good Health in South Africa. | 2026-12-08 |
| NCT05602376Desmond Tutu HIV FoundationImproving HIV Testing, Linkage, and Retention in Care for Men Through U=U Messaging | 2026-12-31 |
| NCT05553236University of California, San FranciscoPragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis | 2027-01 |
| NCT05933226University of Maryland, College ParkProject Khanya: Peer-Delivered Intervention to Improve HIV Medication Adherence and Substance Use in South Africa | 2027-02 |
| NCT05633056Columbia UniversityAn Adaptive Randomized Controlled Trial | 2027-04 |
Add all 9 to your calendar (.ics) → With an account.
Among the 305 studies in HIV Infections with a site in South Africa, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This cohort study plans to investigate associations between the presence of multiple lower genital tract microorganisms in pregnancy and gestational age at birth.
The study enrols pregnant women at one public health care facility in East London, South Africa. At enrolment and 30-34 weeks of pregnancy, participants provide swabs for testing for sexually transmitted infections, vaginal yeasts and genital mycoplasmas; for microscopy and Nugent scoring; and for 16S ribosomal ribonucleic acid gene sequencing and quantification. The primary outcome is gestational age at birth.
Statistical analyses include: regression modelling to explore associations between specific microorganisms (including microbiota) and gestational age at birth; construction of an index of vaginal inflammation, using data about microorganism load and inflammatory potential; classification and regression tree analysis to examine which combinations of microorganisms contribute to earlier gestational age at birth.
Background: Preterm birth complications are the most common cause of death in children under 5 years. In South Africa, the prevalence of both genital tract infections and adverse pregnancy outcomes are high. This study takes a holistic approach, investigating both the presence and quantity of multiple lower genital tract microorganisms, including vaginal microbiota, in pregnancy and their associations with gestational age at birth. Specific objectives are to explore: (1) the association between the presence of specific lower genital tract microorganisms and gestational age at birth (primary outcome), as well as secondary adverse pregnancy outcomes; (2) the association between quantified load of vaginal and sexually transmitted microorganisms and gestational age at birth (primary outcome) as well as secondary adverse pregnancy outcomes; and (3) the combinations of microorganisms that are most strongly associated with earlier gestational age at birth.
Methods: This prospective closed cohort study follows women enrolled during pregnancy until after they give birth. This cohort study is part of a larger project, called Philani Ndiphile (meaning 'be healthy and I will be healthy' in isiXhosa).
A trained study field worker checks for eligibility and obtains written informed consent. A study nurse performs an abdominal ultrasound to estimate the gestational age and confirm eligibility.
At the enrolment visit and a follow-up visit at 30-34 weeks, a study nurse collects vaginal specimens for: on-site testing for Chlamydia trachomatis and Neisseria gonorrhoeae (with antibiotic treatment if positive); and offsite testing for: Nugent scoring; detection and quantification of Mycoplasma genitalium, M. hominis, Ureaplasma. parvum, U. Urealyticum, Trichomonas vaginalis, Candida spp. and 16S rRNA amplicon sequencing for vaginal microbiota analyses.
At a post-natal visit, 3-6 days after giving birth, a study nurse collects information about the birth outcome.
Statistical analyses include:
Objective 1. a) univariable and multivariable regression analyses for associations between specific microorganisms and gestational age at birth. b) compositional multivariable analysis methods to analyse individual taxon relative abundances and mixed effects models to assess associations between pregnancy outcome and vaginal microbiota diversity, vaginal microbiota types and absolute abundances of predefined bacterial groups.
Objective 2. Development of a 'vaginal inflammation index', based on quantification of the vaginal microbiota and their inflammatory potential. This vaginal inflammation index will be analysed as a fixed effect in mixed effects models with pregnancy outcomes.
Objective 3. Classification and regression tree analyses to examine the combination of microorganisms that best predicts earlier gestational age at birth.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
This study's enrollment of 603 is above the median of 200 across 781 observational studies indexed under HIV Infections.
Browse HIV Infections studies →University of Bern is the lead sponsor of 209 studies on the registry; 46 are open to participants now.
Compared within HIV Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sexually Transmitted Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Pregnant women receiving antenatal care at one primary health care facility in Buffalo City Metropolitan Municipality, Eastern Cape Province, South Africa.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No intervention. Followed during pregnancy at baseline and 30-34 weeks. Followed after delivery at 3-6 days.
Other: No intervention
No intervention, observational cohort study
Gestational age at birth
Gestational age in days, estimated using data from obstetric ultrasound at enrolment visit
Time frame: Recorded within 2 weeks of delivery
Preterm birth
Number of babies liveborn before 37 completed weeks of pregnancy, estimated using data from obstetric ultrasound at enrolment visit
Time frame: Recorded within 2 weeks of birth
Low birth weight
Number of babies with birth weight \<2500g
Time frame: Measured within 72 hours of birth
Miscarriage
Number of foetuses delivered dead before 28 completed weeks of pregnancy or with birth weight below 1000g. Gestational age estimated using data from obstetric ultrasound at enrolment visit
Time frame: Collected throughout pregnancy until delivery
Stillbirth
Number of foetuses delivered dead at or after 28 completed weeks of pregnancy or with birth weight above 1000g at delivery. Gestational age estimated using data from obstetric ultrasound at enrolment visit
Time frame: Collected throughout pregnancy until delivery
Prevalence of microorganisms
Number of women with a specific microorganism / number of women tested
Time frame: Measured at enrolment visit and at 30-34 week visit
Incidence of microorganisms
Number of women with new detection of a specific microorganism per 1000 woman years of follow-up
Time frame: Measured at 30-34 week visit
Plan to share: No
Ran from Mar 2021 to primary completion in Apr 2024, 37 months.
Of 187 non-industry observational studies under HIV Infections, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's 37 months is close to that.
Counting every sponsor, half of 201 studies reached it within 38 months; a quarter within 16 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.